Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer
- 19 Downloads
A Phase II trial of an intravenous preparation of Hexamethylmelamine was performed in ovarian cancer. Patients who had received prior Platinum based chemotherapy and had measurable disease were eligible. Among 15 evaluable patients, there were no objective responses. Two patients did show clinical and laboratory evidence of improvement. Toxicity was predominantly nausea and vomiting with minimal other toxicity. This intravenous form of Hexamethylmelamine has not shown meaningful activity in ovarian cancer patients who have failed prior platinum treatment.
Key wordshexamethylmelamine ovarian cancer chemotherapy ovarian cancer
Unable to display preview. Download preview PDF.
- 1.Foster BJ, Handing BJ, Lelaynd-Jones B, Hoth D: Hexamethylmelamine: critical review of an active drug. Can Treat Rev 13:197–217, 1986Google Scholar
- 2.Ames MM, Kovach JS: Parenteral formulation of hexamethylmelamine potentially suitable for use in man. Can Treat Rep 66(7), 1982Google Scholar
- 3.Ames MM, Richardson RL, Kovach JS, Moertel CG, O'Connell MJ: Phase I and clinical pharmacological evaluation of a parenteral hexamethylmelamine formulation. Can Res 50:206–210, 1990Google Scholar
- 4.Stehman FB, Ehrlich CE, Callangan MF: Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Gyne One 17:189–195, 1984Google Scholar
- 5.Rosen GF, Lurain JR, Newton M: Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Gyne Onc 27:173–179, 1987Google Scholar
- 6.Manetta A, MacNeill C, Lyter J, Scheffler B, Podczaski ES, Larson JE, Schein P: Hexamethylmelamine as a single second-line agent in ovarian cancer. Gyne Onc 36:93–96, 1990Google Scholar